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ABSTRACT
Recent reports usin g historical cont ro ls or regist ry coho rts sugges t, resp ectively, eit he r an increa se in th e mOr1alit) '
or a de crease in th e in cid en ce of hep ati c veno- occlusive disease (VO D) with th e ad m in istration o f int r:\\,cn ous
imm unoglobulin (lVlg) after bone marrow rranspl antation. T hese divergent res ults prompted us to co nduc t a ret ro-
spective analysis of two ra ndomize d clinical trials co nducted at our ce nter to det ennine th e effect of IVIg infusions
on the development and severity of VOD. Pati ents were randomized to receive (n =318) or not to receive (n =3 15)
IVlg prophylaxis afte r human leukocyt e antigen -identical sibling (n= 4 14) , mi sm at ch ed or unrelat ed (n = 178), or
autologo us or syngeneic (n= 4 1) marrow transplantation. To detennine th e rel at ion sh ip of IVIg to th e devcloplJlent
and seve rity of VO D, a sing le ob server reviewed data displays crea te d for each pati ent for gr:lding VO D wit!\llUt
knowledge of patient IVIg usc. In thi s anal ysis, VO D was defined as hyperbiliruhinemiu ", 2.0 mg/dL before d'l)' 20
and abru pt weight ga in ", 2% hefore day 14 po sttranspl anr in th e abse nce of other causes of liver disease. Hep:,tic
VO D developed in 235 (37%) of th e 633 randomized pati ents. 0 evide nce fo r VO D was found in 23 0 (.l6%)
pati ents. T he rem aining 168 (27 %) patients were classified as having liver disease o f un cert ain e tio logy, lI ep:,tic
VO D was judged to be severe in 63 (10 %) and mild o r moderate in 172 (27%) pati ents. The numher of pat ient S
developing any VOD o r severe VO D was similar between those rando mized to IVIg prophylaxis and unt reat ed con-
trol s (11 5 vs, 120 and 32 vs. 3 1, res pectively). Logi sti c regression models ide ntified severa l cova riares as sign ific:1I1t (P
< 0.01 ) factors associate d with th e development o f seve re VO D. Increased ris k occu rt·ed with elevate d pret r:lllspl:1I1t
se ru m aspartate am inotra ns ferase (odds ra tio IOn] = 2.64) and ea rlier yea r of rrun splant (O n = .l .73); decreased risk.
occurred with autologous or twin donors (On = 1I.1I,) and acute myeloid leukem ia (On = 1I.39) . The development of
any VOD was associ at ed with an elevat ed pret ransplanr alkalin e phosphatase (On = 4.1 ), pretranspl ant usc of v:u1-
co myci n (O R = 1.6) or amphotericin (O n = 3.1I), posttransplant usc of cyc lospo rine (O lt = 2.5), old er pat ient :I~e
(O R = 1.03), and ohesiry (O R = 0.78). " 'e conc lude d fro m th e contro lled trials of 6H p.ui euts that th e :Illminis tr.
'
-
rion oflVl g did not influ en ce th e development or severity of VO D after hone m arrow t ran splantation.
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INTRODUCTION
Vc no -occlusiv e d isease (VO l)) of th c liver is a majo r
ca use of rcgimcn - rc lntcd mo rbidi ty and mort al ity fo ll(l\l' ill ~
aut o logou s and alloge neic hen uuopo ict ic cel l t rans planW-
tion 11- 3/ . Bet ween 10 and 50 % of pa ti ent s und c rgoin~
IVlgandtheRisko/von
~~ood or marro~ transplantation develop liver toxicity from
V~;reloa?l~tlve conditioning regimen [4-6]. Hepatic
d IS a clinical syndrome of liver damage following high-r~:e r3o~eductive therapy, which results in a case fatality
We' ~ .-50% and is characterized by a triad of abrupt
u Ig t gain caused by fluid retention, hepatomegaly or rightu~~er q~adrant pain, and jaundice developing early after
esta~~fs~ng transplant [1,2,7,8]. The diagnosis of VOD is
du ' ed when two of these three events are observed
[7~]n~~,h~ first 20 days after cytoreductive conditioning
to' h~ 10lcal fea~res ~fVOD stem from extensive dan:age
he ~atoeytes, smusoldal endothelial cells, and terminal
ofratlc venules in zone 3 of the liver acinus, with death
[4:n;e,sulting from renal and cardiorespiratory failured~]i nor reports have identified several risk factors for the
Si;e ~pmentof severe VOD, which include increased inten-
pe ? the preparative regimen, hepatitis before transplant,
dorslsteht fever during conditioning therapy, patient age,
ab~or. u~an leukocyte antigen (lILA) disparity, prior
ti °crnallrradiation, increased doses of total-body irradia-
onR BI), and a second marrow transplant [8-13].
coh ecent studies using historic controls [14] or registry
Illo or~ [15] suggest, respectively, either an increase in the
Us r~l~ or a decrease in the development ofVOD with the
tr e 0 llOtra~enous immunoglobulin (IVIg) during marrow
inans~ antatlon. In the former study, the incidence of VOD
pr a SIngle. institution was 16% among 45 recipients of IVIgno~phrlaX1s compared with 6% among 53 historic controls
occu~1Ve~ IVIg (p == not significant [NS]); fatal VOD
the red ~n 11% of the IVIg group compared with none of
in .SIStorlc controls (p == 0.02) [14]. In the latter study, the
teCI ence of VOD in a registry report from 200 transplant
w·:~Was 6% (95 of 1609), and, for patients conditionedd~ I ~I and given IVIg prophylaxis, the odds ratio (OR) of
o;~30p1Og VOD was significantly reduced (OR == 0.26, P=
ti' ) [15]. These divergent results with IVIg administra-
Con prompted us to conduct a retrospective analysis of two
pO~trol1ed trials conducted at our center that randomized
r:tlents to receive or not to receive IVIg prophylaxis. We
vb~t, the risk factors' for the development and severity of
10this setting.
~ATERIALS AND METHODS
tUdy design and definitions
ou IWe conducted a retrospective analysis of patients previ-
19~j enrolled in two trials that occurred between 1986 and
did and randomized patients who either did (n=318) or
III nor (n=315) receive IVIg prophylaxis [16,17]. The pri-
an~ry endpoint of the current analysis was the development
severity ofVOD of the liver.
of For purposes of this study, VOD was defined by values
ab serum bilirubin ;;::2.0 mg/dL (34.2 umol/L) and an
OcruPt,weight gain ;;::2% above the baseline body weight
hocurr~ng early after transplant in the absence of graft-vs.-
\V st disease (GVHD). The lone grader of VOD (G.B.M.)
as blinded to patient use of IVIg. Graphical displays of
pre,- and posttransplant percent weight change and aspartate
~~Inotransferase (AST), bilirubin, and alkaline phosphatase
\Va ?es were constructed for each patient (Fig. 1). Body
eights and liver function tests were obtained 2-3 times
I1B&MT
weekly until day 100 posttransplant, Acute GVHD was
graded as previously reported [18,19].
Patient data sets were analyzed and liver disease was
defined according to the following criteria [8]:definite VOD,
serum bilirubin ;;::2.0 mg/dL by day 20 and weight gain ;;::2%
by day 14 posttransplant; severe VOD, VOD that did not
resolve before going home at day 100 or death, whichever
occurred first; no VOD, all values of bilirubin remained <2.0
mg/dL through day 20 and weight gain <5% through day
14. Liver disease of uncertain cause was defined as producing
values of bilirubin ;;::2.0 mg/dL and weight gain ;;::2% before
day 28 but not before day 14, bilirubin ;;::2.0 mg/dL and
weight gain <2% before day 28, or bilirubin <2.0 mg/dL
and weight gain ;;::5% before day 14. Patients with hyper-
bilirubinemia that could be explained by GVHD were also
classified as having liver disease of uncertain cause.
Risk factors
Pretransplant liver function values and weights were
recorded starting at day -14, before the start of cytoreduc-
tive conditioning. Use of acyclovir, vancomycin, or ampho-
tericin was recorded if administered before the start of con-
ditioning. Other pretransplant study variables are listed in
Tables 1 and 2.
Transplant regimen
Patients with malignant diseases received 120 mg/kg of
cyclophosphamide (Cy) and either busulfan or, more com-
monly, 6-7 cGy per minute of fractionated TBI (1200-1500
cGy) from opposing cobalt sources given over several days.
Patients with aplastic anemia were prepared with 200 mglkg
Cy alone. The day of marrow infusion was designated as day
0, and methotrexate and cyclosporine were administered
after allogeneic transplantation to prevent acute GVHD
[20]. T cell depletion of the marrow was rarely performed.
Supportive care during and after conditioning included the
administration of oral trimethoprim-sulfamethoxazole to
prevent P. carinii infection and systemic antibiotics to treat
infection during neutropenia. Cytomegalovirus (CMV)-
seronegative patients received blood from seronegative
donors or leukocyte-depleted blood products. After August
1991, CMV-seropositive patients received ganciclovir when
either neutrophil counts recovered or CMV antigenemia
developed [21]. After March 1992, all patients received flu-
conazole to prevent fungal infection [22].
IVlg protocols
Consent forms were approved by the Institutional
Review Board and all data collection and analyses were per-
formed at the Fred Hutchinson Cancer Research Center,
independently of the study sponsor. Those patients random-
ized to receive IVIg were given Gamimune N (Miles, Phar-
maceutical Division, Biological Products, \-Vest Haven, CT)
starting on day -7 at a dose of either 500 mg/kg/week or
100 mg/kg every 3 days until day 90; thereafter, some con-
tinued to receive monthly immunoglobulin until day 360
[16,17]. Patients randomized to weekly dosing were enrolled
between 1986 and 1987 (n=382), and those given every 3
days dosing were enrolled between 1991 and 1993 (n=260).
By protocol design, 123 patients from the former group
continued IVIg administration beyond day 90 [17]. The 642
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Figure I. Data display for grading veno-occluslve disease (VOD) for unique patient number (UPN) 03711 .
Increase in weight gain(wghtgain) andserum bilirubin (bili) in theabsence ofcoincident graft-vs.-host disease (GVHD) defined severe VOD. Hyperbilirubine11llfl
persisted untildeath at 8.3 weeks posttransplant. AGVHGRD, acute GVlfD grade.
patients in the two studies were assigned to strata according
to the following criteria: patient age «20 vs. ~20 years),
Table I. Characteristics of thestudy groups
Group
Factor Control IVlg
Number evaluable patients 315 318
Type of transplant
Allogeneic
HLA-Identlcal sibling 203 211
Mismatched/unrelated 90 88
Autologous/syngeneic 11 19
Disease
Chronic myelogenous leukemia 100 87
Acute myeloid leukemia 88 88
Acute lymphocytic leukemia 52 66
Aplastic anemia/other nonmalignant disorders 19 16
Hodgkin's disease/non-Hodgkin'. lymphoma 37 39
Myelodysplastlc syndrome 19 22
Conditioning regimen
Cyclophosphamide only 2 7
Cyclophosphamide and busulfan (no TBI) 47 49
Cyclophosphamide and TBI (1200 cGy) 60 66
Cyclophosphamide and TBI (> 1200 cGy) 139 123
llLA, human leukocyte antigen; IV/g, intravenous immunoglobulin; TBI,
total-body irradiation.
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type of transplant (lILA-identical related vs. lILA-noniden-
tical/unrelated vs. autologous/syngeneic vs. T cell depleted),
GVnn prophylaxis (methotrexate/cylcosporine vs, cyd~­
sporine/prednisone vs. cyclosporine), infection prophylaXIS
(laminar airflow isolation vs. normal room), pretransplanJ
CMV antibody status (positive vs. negative), and planne
use of hematopoietic growth factors (yes vs. no). Random-
ization was performed within each stratum to ensure bal-
ance between the IVIg recipients and the control groUP'
Nine patients were excluded because of death before day 5
or absence of relevant information in their charts, leaving a
cohort of 633 evaluable individuals.
Statistical methods
Multivariable stepwise logistic regression models of
VOD were fit by including variables for which an association
was previously identified [8]. These factors included prepara-
tive regimen (Cy + > 1200 cGy TBI, Cy + 1200 Gy TBI,
chemotherapy only [no TBI or busulfan], Cy + busulfan,
and other chemotherapy + TB!); underlying disease (chron-
ic myelogenous leukemia, acute myeloid leukemia, acu~e
lymphocytic leukemia, myelodysplastic-syndrorne, aplastIC
anemia, and other nonmalignant disorders); remission statuS
at transplant (relapse, remission, chronic phase, accelerated
phase, or blast crisis); and type of transplant (lILA-matched
sibling, mismatched/unrelated, or autologous/syngeneic).
Reference groups used in the multivariable analyses are given
above. Other pre transplant characteristics included in the
lVIg andthe Risk ofVOD
Table 2 J>r,
• etra7lSfJ/ant characteristics Table 3. Posttransplant liverdisease in 633 patients
Group Factor Patient group Number of patients'
~bfessionmodels are listed in Table 2. Nonsignificant vari-
P ~s Were deleted using a backwards elimination procedure.v~~nts with liver disease that could not be classified as
of (~:: 168) were excluded from these analyses. Because
w multIple comparisons, significance values less than 0.01
o~rt Considered evidence of association;p between 0.05 and
. Was considered suggestive of an association.
RESULTS
Patients
p :fable 1 presents characteristics of the 633 patients.
laa~ents randomized to control (no IVIg) or IVIg prophy-
I ~s W~re well matched for the type of transplant, under-
rnf dIsease, and conditioning regimen. As shown in Table
b~l~ eV~ted values of serum AST, alkaline phosphatase, and
(~~~bJn were noted before the start of conditioning in 125
in ;),71 (11%), and 34 (5%) patients, respectively. Persist-
obg ever during conditioning up to day 5 posttransplant was
d s~rved in 512 (81%) patients. Medications administered
alunn~ conditioning or within five days after transplant are
So gIven in the table.
liver disease
. By day 20 posttransplant, 403 of the 633 patients
eVlDced liver disease (fable 3). Of these, 168 had liver dis-
~se of uncertain etiology and 235 (37%) had VOD. Of
ese 235 patients, 63 had severe VOD. As shown, the pro-
257
57
I
64
250
I
p
0.0081
0.0022
0.0072
0.0089
230 (36)
168 (27)
235 (37)
115 (18)
120(19)
32 (5)
31 (5)
2.64
3.73
0.09
0.39
Odds ratio
No liver disease
Uncertain cause
VOD
IVlg
Control
IVlg
Control
Liver disease before
day 20 posttransplant
Any VOD development
Severe VOD development
Table 4. Militivariable analysis: development ofsevere VOD
Risk factor
Elevated pre transplant AST
Earlier year of transplant
Autologous/syngenelc transplant
Acute myeloid leukemia
portions of patients with any VOD or severe VOD were
similar in controls and IVIg recipients.
Multivariable analysis of VOD
Table 4 presents results of analyses of factors associated
with the development of severe VOD. Factors associated
with an increased risk of severe VOD included elevated AST
before the start ofconditioning and earlier year of transplant.
Factors associated with a decreased risk included autolo-
gous/twin transplants and a diagnosis of acute myeloid
leukemia. IVIg had no significant association (p = 0.22).
Table 5 presents the results of multivariable analyses for
development of VOD. Results of the current study (right
columns) are displayed in relation to a prior prospective
Seattle study (left columns) and a registry report (middle
columns). In the current study, an increased risk of develop-
ing any VOD was associated with elevated alkaline phos-
phatase before the start of conditioning, the administration
of vancomycin or amphotericin during conditioning, use of
posttransplant cyclosporine, and patient age. Obesity was
associated with a reduced risk of VOD while IVIg had no
significant association (p = 0.089).
"Numbers in parenthesis arepercents of thecohort of 633 patients.
VOD, ueno-occiusiue disease of theliver.
AST, aspartate eminotransferase.
DISCUSSION
Advances in supportive care techniques during the past
decade have significantlyreduced transplant-related mortality
from infection and GVHD and improved outcome for
patients with malignant and nonmalignant diseases [19-24J. In
contrast, the incidence ofVOD during this time has increased
from 21 to 54% [1,8J. Hepatic VOD represents a leading
cause of death after autologous and allogeneic hematopoietic
cell transplantation, especiallyamong patients receivinginten-
sified pretransplant conditioning regimens [2,6,7,l1J. Thus,
297
21
o
276
42
o
250
68
o
55
262
I
IVlg
(n=318)
234/8410
1171201/0
551263/0
267/5110
284/34/0
8/31010
285
29
I
301
13
I
234/80/1
116/198/1
421272/1
259/5511
271143/1
8/306/1
Factor Control
_ (n=315)
SerUlll liver ~ IA unct on test values before conditioning
Spartate aminotransferase
Norlllal
Elevated
Data Illissing
Alkaline phosphatase
NOrIllal
Elevated
Data Illissing
Total serum bilirubin
Normal
Elevated
Data missing
Fever:>38·C d •
Ab urlng conditioning or to day 5sent
~resent (duration >5 days)
ata Illissing
Drugsgive d
A n urlng conditioning or to day 5
Vcyclovlr (+I-/data missing)
AancOmycln (+I-/data missing)
IllPhotericin (+I-/data missing)
Cyclospo' (
M rlne +I-/data missing)ethotrex t ( •G a e +I-/data missing)~+I-/data missing)
+, 1I11mber ,I' .
_ oJ patients whoreceived thedrug.
,number if . .GM-C 0 patients who didnotreceive thedrug.
'SF, granUlocyte-macrophage colony-stimulatingfactor.
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Table S. Multivariable analysis: development of VOD
Seattle study· IBMTR studl Current study
(severe VOO) (any VOO) (any VOO)
-Pretransplant factors Odds ratio p Odds ratio p Odds ratio p
-
Uver disease" 4.6 0.0001 1.9 0.05 4.1 0.0002
High-dose regimen 2.8 0.01 2.8 0.0001 NS
Vancomycin use 2.9 0.003 NA 1.6 0.0283
Fungal disease/amphotericin NS 4.1 0.011 3.0 0.0010
Acyclovir use 4.8 0.02 NS NS
Cyclosporine use NA NS 2.5 0.0031
Mismatched/unrelated donor 2.4 0.02 NA NS
Patient age NS 1.8 0.05 1.03d 0.0002
IVlg use NA 0.26· 0.003 NS
Obesity NA NA 0.78' 0.0014
-
'Reference 8.
blnternational Bone Marrow Transplant Registry [15].
'Elevated aspartate aminotransferase, history liverdisease, orelevated alkaline phosphatase, respectively, in thethree studies.
;Peryearoflife.
'In TBI recipients givenIVIg.
[Per 10% above ideal body weight.
NA, notanalyzed; NS, notsignificant.
agents that alter the incidence or fatality ofVOD are of espe-
cial importance to transplant physiciansand patients.
Recently two reports using historic controls or registry
cohorts suggested an increase in the mortality or a decrease
in the incidence afVOD in patients given IVIg during mar-
row transplantation [14,15). To clarify these divergent
results, we conducted a retrospective analysis of controlled
trials that were conducted at our center, randomizing
patients to receive or not to receive Mg prophylaxis start-
ing on day -7 before transplantation. Incidence and fatality
rates of VOD were not previously available because VOD
was neither recorded as an event on the case report forms
nor consistently defined in the medical records.
To retrospectively determine the incidence and severity
of VOD from available medical summaries (in which serial
liver size and right upper quadrant pain determinations were
not uniformly recorded), we identified VOD in individuals
experiencing both weight gain and elevated serum bilirubin
levels early after transplantation. Graphical displays (Fig. 1)
were constructed for each patient and VOD was graded by a
lone reviewer blinded to patient use of Mg. Undoubtedly,
the exclusion of hepatomegaly and pain as one of the signs of
VOD led to some reduction in the number of individuals
with definite VOD and an increase in those with liver disease
of uncertain cause. The proportion of patients with any
VOD (37%) and severe VOD (10%) in the current study was
lower than that in a recent prospective study from this center
wherein rates were 54% and 15%, respectively [8]. Nonethe-
less, as shown in Table 5, this methodology identified many
of the same risk factors for the development of VOD that
were reported in previous studies [8,15]. Such correlations
suggest that this methodology can reliably detect risk factors
associated with the development and severity ofVOD.
Our results, showing no association between IVIg and
VOD, stand in contrast to two prior reports. The report by
Klaesson et al. that describes increased mortality from VOD
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in IVIg recipients was based on a relatively small sample of
patients who were not randomized, which thus allowed sele~­
tion and reporting bias into the analysis [14]. The study Y
Rozman et al. showing that IVIg recipients had less VOD also
did not involve a randomization to receive IVIg, and repr~­
sents a compilation of data from 200 centers whose defini-
tions ofVOD varied [15]. It is clear that not all posttranspl~nt
liver dysfunction can be readily classified in a binary func~on
as VOD or no VOD. Further, among patients who have h~er
dysfunction posttransplant, there are those whose liver dis-
ease is multifactorial and others who have pathologic process-
es that may mimic VOD. The diseases that make identific~­
tion of VOD difficult include cholangitis lenta (cholest3SIS
related to sepsis), drug-induced cholestasis, congestive hea~t
failure, renal failure, hemolysis, and hyperacute GVHD. \\e
speculate that the registry data may have classified patier:ts
with cholestatic liver disease, especially cholestasis of sepSiS,
as having VOD; thus, one might expect the incidence of sep-
sis and cholestatic liver disease among IVIg recipients to be
lower and would account for the registry findings.
Pretransplant liver disease evidenced by elevated se~m
AST significantly increased the risk of severe VOD, a findtng
repeatedly shown since 1980 [1,13,25). Liver disease coul~
perturb the hepatic metabolism of drugs and detoxification 0
metabolites, thus compounding damage to zone 3 hepatO-
cytes, Sinusoidal endothelial cells in an inflamed liver might
be more susceptible to toxic damage, especially with high-
dose busulfan or Cy regimens [6,26-29]. Conversely, autolo-
gous or twin transplant recipients appear to have a reduced
risk of developing VOD [29]. This finding could be related to
agents given to prevent GVIID after allografting. Methotrex-
ate and cyclosporine are recognized hepatotoxins and are not
used in autologous or syngeneic transplantation [12,29].
Our study confirmed these factors as independently asSO-
ciated with the development of VOD and yielded relative
risk estimates remarkably similar to several prior publica-
IJ1]g andtheRisk ofVOD
~n~. ~ unexpected finding was the apparent reduction in
lit~l~n~l ence ?fVOD in obese individuals. Although there is
sta ~rrelatIon between cyclosporine clearance or steady
ul te vo urne of distribution and obesity [31], one could spec-coatl~ that altered partitioning of cyclosporine metabolites
obu . reduce hepatotoxicity. However, the overall impact of
Onesity on transplant-related mortality is controversial, with
rn e s~dy showing no effect and others showing increased
as°rt~ I~ [24,32,33]. Further confirmation of the apparent
so~atIo~between obesity and VOD is required.
VOD ne Inde~endent risk factor for the development of any
insti ~as patient age. A prospective study of VOD at our
si .~tIon between 1978 and 1980 also found this to be a
oFhcant factor [1]. We speculate that either the metabolismfe c e~otherapy drugs, the proximate cause ofVOD, is dif-
litrent In children than in adults, yielding less toxic metabo-
toe~per Unit dose, or that older patients are more susceptible
and ese metabolites. The absence of a relation between age
co s~~er~ VOD in this and other series [8] suggests that the
rn n~1 ~tIon of age to the incidence of VOD, whatever the
Plec amsm, .does not play an appreciable role in peritrans-
ofa;;t mortahty. Multivariable analysis found that earlier year
sp afsplant was related to the incidence of severe VOD. We
ti;eu .ate that this may relate to patient and regimen selec-
rn f' r.e., during the 1980s patients with advanced stage
inar ancy received pilot regimens of higher-dose condition-li~ . an those in the 1990s. We learned that VOD was dose-
~ng for several of these regimens [34].
pr he. administration of anti-infectives for fever duringdeep~ratIVe conditioning has also been associated with the
va
ve
°pment of VOD [8,15]. Acyclovir, amphotericin, and
ncomy . k r . fl .
and . c~n may serve as surrogate mar ers lor In arnmanon
be InfectIOn. Cytokines, such as tumor necrosis factor, have
tr en associated with the development of acute GVHD and
thansplant-related complications; procoagulant effects of
[3~; cytokines could foster the development of VOD
rn 7]. 'rhus, prevention of infection and release of inflam-
Phatf~ mediators could be a mechanism whereby Mg pro-
se y aXis alters the development or outcome of VOD sinceanv~ral publications have reported an immunomodulatory orno~l-eytokine effect of Mg [16,38-43]. This hypothesis is
ti ~uPported by the data, however, and in the current mul-V~~abl~ analysis we could find no significant association of
WithIVIg administration.
tiv lIn conclusion, we have developed a method to retrospec-
an~ y S~dy the incidence and severity of VOD of the liver
633 apphed this methodology in a blinded manner to study
tri 1marrow graft recipients who participated in randomized
ofV~f IVIg prophylaxis. Increased development or severity
Vat D was associated with pretransplant liver disease (ele-
p ~d AS'r or alkaline phosphatase), earlier year of transplant,tt~ent age, and pretransplant use ofamphotericin. Decreased
tr
S
s of VOD were associated with autologous/syngeneic
ti ansplants, obesity, and acute myeloid leukemia. Adrninistra-
th°n ofIVIg was associated with neither the development nor
e severity ofVOD following bone marrow transplantation.
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